WIP1 Antibody (Rabbit mAb) [J2N2]

CatNo: F9288

    Application: Reactivity:
    • Lane 1: MCF7, Lane 2: Jurkat, Lane 3: A549, Lane 4: F9
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000
    1:50
    1:500
    Application
    WB, IF, FCM
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Mouse, Rat, Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    67 kDa 50 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Human testis tissue; Human lung cancer tissue; Mouse spleen tissue; Rat spleen tissue; MCF7 cells; Jurkat cells; HCT-116 cells; A549 cells; F9 cells; RAW 264.7 cells; PC-12 cells; NIH/3T3 cells
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IF
    Experimental Protocol:
     
    Sample Preparation
    1. Adherent Cells: Place a clean, sterile coverslip in a culture dish. Once the cells grow to near confluence as a monolayer, remove the coverslip for further use.
    2. Suspension Cells: Seed the cells onto a clean, sterile slide coated with poly-L-lysine.
    3. Frozen Sections: Allow the slide to thaw at room temperature. Wash it with pure water or PBS for 2 times, 3 minutes each time.
    4. Paraffin Sections: Deparaffinization and rehydration. Wash the slide with pure water or PBS for 3 times, 3 minutes each time. Then perform antigen retrieval.
     
    Fixation
    1. Fix the cell coverslips/spots or tissue sections at room temperature using a fixative such as 4% paraformaldehyde (4% PFA) for 10-15 minutes.
    2. Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Permeabilization
    1.Add a detergent such as 0.1–0.3% Triton X-100 to the sample and incubate at room temperature for 10–20 minutes.
    (Note: This step is only required for intracellular antigens. For antigens expressed on the cell membrane, this step is unnecessary.)
    Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Blocking
    Add blocking solution and incubate at room temperature for at least 1 hour. (Common blocking solutions include: serum from the same source as the secondary antibody, BSA, or goat serum.)
    Note: Ensure the sample remains moist during and after the blocking step to prevent drying, which can lead to high background.
     
    Immunofluorescence Staining (Day 1)
    1. Remove the blocking solution and add the diluted primary antibody.
    2. Incubate the sample in a humidified chamber at 4°C overnight.
     
    Immunofluorescence Staining (Day 2)
    1. Remove the primary antibody and wash with PBST for 3 times, 5 minutes each time.
    2. Add the diluted fluorescent secondary antibody and incubate in the dark at 4°C for 1–2 hours.
    3. Remove the secondary antibody and wash with PBST for 3 times, 5 minutes each time.
    4. Add diluted DAPI and incubate at room temperature in the dark for 5–10 minutes.
    5. Wash with PBST for 3 times, 5 minutes each time.
     
    Mounting
    1. Mount the sample with an anti-fade mounting medium.
    2. Allow the slide to dry at room temperature overnight in the dark.
    3. Store the slide in a slide storage box at 4°C, protected from light.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    WIP1 Antibody (Rabbit mAb) [J2N2] detects endogenous levels of total WIP1 protein.
    タンパク質の局在
    細胞質、細胞核
    Uniprot ID
    O15297
    Clone
    J2N2
    Synonym(s)
    WIP1, PPM1D, Protein phosphatase 1D, Protein phosphatase 2C isoform delta, Protein phosphatase magnesium-dependent 1 delta, p53-induced protein phosphatase 1, PP2C-delta
    Background
    PPM1D, also known as wild‑type p53‑induced phosphatase 1 (WIP1), is a nuclear serine/threonine phosphatase of the PP2C family that is transcriptionally induced by p53 after genotoxic stress and acts as a homeostatic regulator of the DNA damage response by dephosphorylating multiple substrates of ATM and ATR kinases. The protein contains a conserved PP2C catalytic domain and regulatory regions that allow selective recognition of phospho‑Ser/Thr motifs on key checkpoint and stress signaling proteins, enabling WIP1 to function as a “reset” enzyme that terminates checkpoint signaling once damage has been addressed. WIP1 directly dephosphorylates p53 on residues targeted by ATM/ATR, reduces p53 transcriptional activity and forms a negative feedback loop in which p53 induces PPM1D expression and the resulting phosphatase attenuates p53‑dependent cell-cycle arrest and apoptosis, restoring proliferative capacity after DNA repair. The phosphatase also dephosphorylates and inactivates several other tumor suppressors and checkpoint components, including ATM, Chk1, Chk2, γH2AX and p38 MAPK; in the case of Chk2, ATM phosphorylates Thr68 to promote Chk2 dimerization and activation, and WIP1 binds Chk2 and removes phospho‑Thr68, thereby opposing Chk2 activation and suppressing its contribution to the G2/M DNA damage checkpoint. Through concerted dephosphorylation of these substrates, WIP1 reduces DDR signaling thresholds, maintains cells competent for re‑entry into the cell cycle from G2 phase and modulates senescence, apoptosis and autophagy decisions under stress. Regulation of WIP1 itself occurs at multiple levels: p53 drives its transcription, microRNAs such as miR‑16 limit WIP1 expression early in DDR to prevent premature checkpoint termination, and APC/C–Cdc20‑mediated ubiquitin–proteasome degradation lowers WIP1 levels during mitosis, a state in which DNA damage largely remains unrepaired and increased DDR sensitivity in the following G1 phase is beneficial for repair. Oncogenic roles for PPM1D arise when this finely tuned balance is disrupted; the gene is amplified and overexpressed in several human cancers, including breast and ovarian carcinomas, and WIP1 cooperates with classic oncogenes in fibroblast transformation assays, consistent with its capacity to suppress p53, ATM, p16INK4a and ARF pathways and to weaken stress-induced barriers to proliferation. Gain‑of‑function truncating mutations in PPM1D have been identified in hematopoietic and solid tumors and confer enhanced phosphatase activity or stability, impair p53‑mediated checkpoints after DNA damage and predispose cells to tumorigenesis, while Ppm1d‑null mice show resistance to tumor development, supporting a causal role for WIP1 dysregulation in cancer. WIP1 is also expressed in hematopoietic progenitors, lymphoid and myeloid cells, where it influences differentiation and immune function, and its loss leads to immunodeficiency and pro‑inflammatory phenotypes, reflecting its broader role in stress response, NF‑κB and mTOR pathway modulation and tissue homeostasis.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください